about
Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastomaReduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma.Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era.Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2 immunotherapy and isotretinoin: a prospective Phase II study.Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.Hyperfractionated low-dose (21 Gy) radiotherapy for cranial skeletal metastases in patients with high-risk neuroblastoma.High-dose cyclophosphamide-irinotecan-vincristine for primary refractory neuroblastoma
P50
Q33836091-33E06CCE-3971-4C12-B449-C10F82DBF088Q34378537-2D1B7F9E-D1A9-4281-93D6-6E80335869EFQ35077703-9FA3B2E9-8981-4E4F-AC6C-9E07BC45A24BQ35798960-776B2FA3-34F2-49DF-8D80-8D283599C48DQ36782374-23C88799-B3D4-40FE-B249-CD308724FE23Q41634067-5A69A71A-CA6F-4E4A-B18D-88CF041DEA79Q85174922-668F7ADB-0F63-43FE-8FF8-E5DF243F142C
P50
description
researcher ORCID ID = 0000-0002-5223-6504
@en
name
Karima Yataghene
@ast
Karima Yataghene
@en
Karima Yataghene
@es
Karima Yataghene
@nl
type
label
Karima Yataghene
@ast
Karima Yataghene
@en
Karima Yataghene
@es
Karima Yataghene
@nl
prefLabel
Karima Yataghene
@ast
Karima Yataghene
@en
Karima Yataghene
@es
Karima Yataghene
@nl
P31
P496
0000-0002-5223-6504